We will measure this outcome by applying the WOMAC questionnaire compared with baseline therapy. The primary efficacy outcome will be defined as the percentage of patients having a 50% decrease in the summed score for the WOMAC pain subscale from baseline to week 24. The difference in ranges of motion will be statistically compared at different time points between the two groups to determine the difference in improvement between the two compared to baseline. Physical exams will be performed to assess range of motion of the hip joint. All of the study subjects will be blinded to which treatment that they are assigned to. ![]() ![]() The sub-investigator will be blinded to the treatment throughout the study. All of the follow up visits, clinical assessments and outcome scores will be performed by the sub-investigator, who will also be the examining physician. The PI will only be involved in the initial assessment of the patient and the actual injections. The Primary investigator will be unblinded to the treatment that the subject is randomized to. If the patient has OA in both hips, they will be randomized to receive the same injection in both hips. Patients, which meet inclusion criteria, are confirmed eligible, and agree to enroll in the study, would be randomized and treated with either three intra-articular PRP injections or three intra-articular Hyaluronic Acid injections. Secondarily, the study aims to evaluate the safety and feasibility of both medications delivered. Hyaluronic Acid for symptomatic early OA of the hip. The primary objective of this study is to compare the clinical efficacy of intra-articular injections of Platelet Rich Plasma (PRP) vs. Currently, the most suitable route for administering OA therapy appears to be intra-articular injections that allow accumulation of critical doses of the drug within the damaged area and also reduce the risk of systemic side effects. Analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) have suboptimal effectiveness, and there is concern of systemic side effects.Ī large challenge is the development of appropriate and effective therapy in patients with OA. Unfortunately, there is no agents available that halt OA progression. Osteoarthritis (OA) is a common, painful condition affect adults and causes mobility disability in the United States and Europe. Why Should I Register and Submit Results?.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |